Ritlecitinib (Synonyms: PF-06651600)
目录号: PL01124 纯度: ≥99%
CAS No. :1792180-81-4
商品编号 规格 价格 会员价 是否有货 数量
PL01124-5mg 5mg ¥948.00 请登录
PL01124-10mg 10mg ¥1510.00 请登录
PL01124-25mg 25mg ¥3021.00 请登录
PL01124-50mg 50mg ¥4821.00 请登录
PL01124-100mg 100mg ¥7714.00 请登录
PL01124-200mg 200mg 询价 询价
PL01124-500mg 500mg 询价 询价
PL01124-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1044.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Ritlecitinib
中文别名
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
英文名称
Ritlecitinib
英文别名
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one;2OYE00PC25;PF06651600;ritlecitinib (proposed INN);GTPL9559;BCP24778;example 5 [WO2015083028];DB14924;compound 11 [PMID: 28139931];S8538;PF06651600;PF 06651600;1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate;1-[(2S,5R)-2-methyl-5-;Ritlecitinib
Cas No.
1792180-81-4
分子式
C15H19N5O
分子量
285.34
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Ritlecitinib (PF-06651600) 是一种口服有效的,选择性的 JAK3 抑制剂,IC50 值为 33.1 nM。
生物活性
Ritlecitinib (PF-06651600) is an orally active and selective JAK3 inhibitor with an IC 50 of 33.1 nM.
性状
Solid
IC50 & Target[1][2]
JAK3 33.1 nM (IC50)
体外研究(In Vitro)
Ritlecitinib is a potent JAK3-selective inhibitor which can inhibit the JAK3 kinase activity with an IC50 of 33.1 nM but without activity (IC50>10?000 nM) against JAK1, JAK2, and TYK2. Ritlecitinib inhibits the phosphorylation of STAT5 elicited by IL-2, IL-4, IL-7, and IL-15 with IC50 values of 244, 340, 407, and 266 nM, respectively. Ritlecitinib also inhibits the phosphorylation of STAT3 elicited by IL-21 with an IC50 of 355 nM. Functional assessment in T-cell differentiation assays demonstrate that Ritlecitinib suppresses Th1 and Th17 differentiation as measured by IFNγ, after 5 days under Th1 conditions, and IL-17 production, after 6 days under Th17 conditions, with IC50 values of 30 nM and 167 nM, respectively. Ritlecitinib also suppresses Th1 and Th17 function as measured by the inhibition of IFNγ production
体内研究(In Vivo)
In the rat adjuvant-induced arthritis (AIA) model, Ritlecitinib reduces paw swelling with an unbound EC 50 of 169 nM. Similarly, Ritlecitinib significantly reduces disease severity in the experimental autoimmune encephalomyelitis (EAE) mouse model when dosed either therapeutically at 30 or 100 mg/kg or prophylactically at 20 and 60 mg/kg. The efficacy of Ritlecitinib in these two rodent models of inflammatory and autoimmune diseases illustrates that JAK3-selective inhibition can be sufficient to have disease modifying effects in human diseases. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Telliez JB, et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12):3442-3451.
溶解度数据
In Vitro: DMSO : 125 mg/mL (438.07 mM; Need ultrasonic)H2O : 6.67 mg/mL (23.38 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2